{
  "resourceType" : "Bundle",
  "id" : "bundlepackageleaflet-es-94a96e39cfdcd8b378d12dd4063065f9",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"]
  },
  "language" : "es",
  "identifier" : {
    "system" : "https://www.gravitatehealth.eu/sid/doc",
    "value" : "EU/1/18/1289/001"
  },
  "type" : "document",
  "timestamp" : "2023-06-27T10:09:22Z",
  "entry" : [{
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-es-2a9c4333cfd126f2e7b73ad3cafd6949",
    "resource" : {
      "resourceType" : "Composition",
      "id" : "composition-es-2a9c4333cfd126f2e7b73ad3cafd6949",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"]
      },
      "language" : "es",
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"es\" lang=\"es\"><a name=\"Composition_composition-es-2a9c4333cfd126f2e7b73ad3cafd6949\"> </a><p><b>Generated Narrative: Composition</b><a name=\"composition-es-2a9c4333cfd126f2e7b73ad3cafd6949\"> </a><a name=\"hccomposition-es-2a9c4333cfd126f2e7b73ad3cafd6949\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Composition &quot;composition-es-2a9c4333cfd126f2e7b73ad3cafd6949&quot;  (Language &quot;es&quot;) </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/rmswi/</code>/c97bc0c62de4cf4143e63299ba73c5a3</p><p><b>status</b>: final</p><p><b>type</b>: Package Leaflet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#100000155538)</span></p><p><b>category</b>: Raw <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"CodeSystem-epicategory-cs.html\">Category of EPI</a>#R)</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"#Organization_mah-715f8a161ed438d0584510e5b4512caa\">See above (Organization/mah-715f8a161ed438d0584510e5b4512caa)</a></p><p><b>title</b>: TEST PURPOSES ONLY - Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td>Official <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-composition-attestation-mode.html\">Composition Attestation Mode</a>#official)</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
      },
      "identifier" : [{
        "system" : "https://spor.ema.europa.eu/rmswi/",
        "value" : "c97bc0c62de4cf4143e63299ba73c5a3"
      }],
      "status" : "final",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi/",
          "code" : "100000155538"
        }],
        "text" : "Package Leaflet"
      },
      "category" : [{
        "coding" : [{
          "system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
          "code" : "R",
          "display" : "Raw"
        }]
      }],
      "subject" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "date" : "2022-02-16T13:28:17Z",
      "author" : [{
        "reference" : "Organization/mah-715f8a161ed438d0584510e5b4512caa"
      }],
      "title" : "TEST PURPOSES ONLY - Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion",
      "attester" : [{
        "mode" : {
          "coding" : [{
            "system" : "http://hl7.org/fhir/composition-attestation-mode",
            "code" : "official"
          }]
        },
        "time" : "2022-02-16T13:28:17Z"
      }],
      "section" : [{
        "title" : "B. PROSPECTO",
        "code" : {
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi/",
            "code" : "100000155538"
          }],
          "text" : "B. PROSPECTO"
        },
        "text" : {
          "status" : "additional",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
        },
        "emptyReason" : {
          "coding" : [{
            "system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
            "code" : "unavailable"
          }]
        },
        "section" : [{
          "title" : "PROSPECTO: INFORMACIÓN PARA EL USUARIO",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "PROSPECTO: INFORMACIÓN PARA EL USUARIO"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><a name=\"page1\" id=\"page1\"></a><strong><span>Prospecto: informaci&#243;n para el usuario</span></strong></p><p><strong><span>Biktarvy 50 mg/200 mg/25 mg comprimidos recubiertos con pel&#237;cula</span></strong></p><p><span>bictegravir/emtricitabina/tenofovir alafenamida</span></p><p><strong><span>Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene informaci&#243;n importante para usted.</span></strong></p><ul><li><span>Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li><span>Si tiene alguna duda, consulte a su m&#233;dico o farmac&#233;utico.</span></li><li><span>Este medicamento se le ha recetado solamente a usted, y no debe d&#225;rselo a otras personas aunque tengan los mismos s&#237;ntomas que usted, ya que puede perjudicarles.</span></li><li><span>Si experimenta efectos adversos, consulte a su m&#233;dico o farmac&#233;utico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver secci&#243;n 4.</span></li></ul></div>"
          }
        },
        {
          "title" : "Contenido del prospecto",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "Contenido del prospecto"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ol><li><span>Qu&#233; es Biktarvy y para qu&#233; se utiliza</span></li><li><span>Qu&#233; necesita saber antes de empezar a tomar Biktarvy</span></li><li><span>C&#243;mo tomar Biktarvy</span></li><li><span>Posibles efectos adversos</span></li><li><span>Conservaci&#243;n de Biktarvy</span></li><li><span>Contenido del envase e informaci&#243;n adicional</span></li></ol></div>"
          }
        },
        {
          "title" : "1. Qué es Biktarvy y para qué se utiliza",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "1. Qué es Biktarvy y para qué se utiliza"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span>Biktarvy contiene tres principios activos:</span></p><ul><li><strong><span>bictegravir,</span></strong> <span>un medicamento antirretroviral conocido como inhibidor de la transferencia de las</span> <span>hebras de la integrasa (INI)</span></li><li><strong><span>emtricitabina,</span></strong> <span>un medicamento antirretroviral de un tipo conocido como nucle&#243;sido inhibidor</span> <span>de la transcriptasa inversa (ITIAN)</span></li><li><strong><span>tenofovir alafenamida,</span></strong> <span>un medicamento antirretroviral de un tipo conocido como nucle&#243;tido</span> <span>inhibidor de la transcriptasa inversa (ITIANt)</span></li></ul><p><span>Biktarvy es un comprimido &#250;nico para el tratamiento de la infecci&#243;n por el virus de la inmunodeficiencia humana 1 (VIH-1) en adultos.</span></p><p><span>Biktarvy reduce la cantidad de VIH presente en el organismo. Esto mejora el sistema inmunitario y disminuye el riesgo de desarrollar enfermedades asociadas con la infecci&#243;n por el VIH.</span></p></div>"
          }
        },
        {
          "title" : "2. Qué necesita saber antes de empezar a tomar Biktarvy",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "2. Qué necesita saber antes de empezar a tomar Biktarvy"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong><span>No tome Biktarvy</span></strong></p><ul><li><strong><span>Si es al&#233;rgico a bictegravir, emtricitabina, tenofovir alafenamida</span></strong> <span>o a alguno de los dem&#225;s</span> <span>componentes de este medicamento (incluidos en la secci&#243;n 6 de este prospecto).</span></li><li><a name=\"page2\" id=\"page2\"></a><strong><span>Si actualmente est&#225; tomando alguno de los siguientes medicamentos:</span></strong></li><ul><li><strong><span>rifampicina</span></strong> <span>utilizada para tratar algunas infecciones bacterianas como la tuberculosis</span></li><li><strong><span>hierba de San Juan</span></strong> <span>(</span><em><span>Hypericum perforatum</span></em><span>, hip&#233;rico), un medicamento a base de</span> <span>plantas utilizado para la depresi&#243;n y la ansiedad, o productos que la contengan.</span></li></ul></ul><span>Si est&#225; tomando alguno de estos medicamentos,</span> <strong><span>no tome Biktarvy y consulte a su m&#233;dico</span></strong> <strong><span>inmediatamente.</span></strong><p><strong><span>Advertencias y precauciones</span></strong></p><p><strong><span>Consulte a su m&#233;dico antes de empezar a tomar Biktarvy:</span></strong></p><ul><li><strong><span>Si tiene problemas hep&#225;ticos o antecedentes de enfermedad hep&#225;tica, incluida la hepatitis.</span></strong> <span>Los pacientes que padecen de enfermedades hep&#225;ticas, como la hepatitis B o C cr&#243;nica, y est&#225;n en tratamiento con antirretrovirales tienen m&#225;s riesgo de presentar complicaciones hep&#225;ticas graves y potencialmente mortales. Si tiene infecci&#243;n por el virus de la hepatitis B, su m&#233;dico evaluar&#225; detenidamente la mejor pauta terap&#233;utica para usted.</span></li><li><strong><span>Si tiene hepatitis B.</span></strong> <span>Los problemas hep&#225;ticos pueden empeorar despu&#233;s de dejar de tomar</span> <span>Biktarvy.</span></li></ul><span>No deje de tomar Biktarvy si tiene hepatitis B. Hable antes con su m&#233;dico. Puede consultar m&#225;s detalles en la secci&#243;n 3,</span> <em><span>No interrumpa el tratamiento con Biktarvy.</span></em><p><strong><span>Mientras est&#233; tomando Biktarvy</span></strong></p><p><span>Una vez que empiece a tomar Biktarvy, est&#233; atento a:</span></p><ul><li><strong><span>Signos de inflamaci&#243;n o infecci&#243;n</span></strong></li><li><strong><span>Dolor articular, rigidez o problemas &#243;seos</span></strong></li></ul><strong><span>Si nota cualquiera de estos s&#237;ntomas, informe a su m&#233;dico inmediatamente.</span></strong> <span>Puede consultar</span> <span>m&#225;s informaci&#243;n en la secci&#243;n 4,</span> <em><span>Posibles efectos adversos</span></em><span>.</span><p><span>Aunque no se han observado problemas renales con Biktarvy, existe la posibilidad de que pueda experimentar problemas renales si toma Biktarvy durante un periodo de tiempo prolongado.</span></p><p><span>Mientras est&#233; tomando este medicamento</span> <strong><span>a&#250;n puede transmitir el VIH a los dem&#225;s,</span></strong> <span>aunque un tratamiento antirretroviral eficaz reduzca el riesgo. Consulte a su m&#233;dico sobre qu&#233; precauciones son necesarias para no infectar a otras personas. Este medicamento no es una cura para la infecci&#243;n por el VIH. Mientras usted est&#233; tomando Biktarvy podr&#225; seguir padeciendo infecciones u otras enfermedades asociadas con la infecci&#243;n por el VIH.</span></p><p><strong><span>Ni&#241;os y adolescentes</span></strong></p><p><strong><span>No administre este medicamento a ni&#241;os y adolescentes menores de 18 a&#241;os de edad.</span></strong> <span>No se ha</span> <span>estudiado todav&#237;a el uso de Biktarvy en ni&#241;os y adolescentes menores de 18 a&#241;os de edad.</span></p><p><strong><span>Otros medicamentos y Biktarvy</span></strong></p><p><strong><span>Informe a su m&#233;dico o farmac&#233;utico si est&#225; tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.</span></strong> <span>Biktarvy puede interaccionar con otros medicamentos.</span> <span>Como consecuencia, los niveles sangu&#237;neos de Biktarvy o de otros medicamentos se pueden ver afectados. Esto puede impedir que sus medicamentos funcionen correctamente o empeorar sus posibles efectos adversos. En algunos casos, su m&#233;dico puede tener que ajustar la dosis o comprobar sus concentraciones sangu&#237;neas.</span></p><p><a name=\"page3\" id=\"page3\"></a><strong><span>Medicamentos que nunca se deben tomar con Biktarvy:</span></strong></p><ul><li><strong><span>rifampicina</span></strong> <span>utilizada para tratar algunas infecciones bacterianas como la tuberculosis</span></li><li><strong><span>hierba de San Juan</span></strong> <span>(</span><em><span>Hypericum perforatum</span></em><span>, hip&#233;rico), un medicamento a base de plantas</span> <span>utilizado para la depresi&#243;n y la ansiedad, o productos que lo contengan</span><strong><span>.</span></strong></li></ul><span>Si est&#225; tomando alguno de estos medicamentos,</span> <strong><span>no tome Biktarvy e informe a su m&#233;dico</span></strong> <strong><span>inmediatamente.</span></strong><p><strong><span>Consulte con su m&#233;dico si est&#225; tomando:</span></strong></p><ul><li><strong><span>medicamentos utilizados para tratar el VIH y/o la hepatitis B</span></strong> <span>que contengan:</span></li><ul><li><span>adefovir dipivoxil, atazanavir, bictegravir, emtricitabina, lamivudina, tenofovir alafenamida o tenofovir disoproxilo</span></li></ul><li><strong><span>antibi&#243;ticos, utilizados para tratar las infecciones bacterianas</span></strong><span>, que contengan:</span></li><ul><li><span>azitromicina, claritromicina, rifabutina o rifapentina</span></li></ul><li><strong><span>antiepil&#233;pticos,</span></strong> <span>utilizados para tratar la epilepsia, que contengan:</span></li><ul><li><span>carbamazepina, oxcarbazepina, fenobarbital o fenito&#237;na</span></li></ul><li><strong><span>inmunosupresores,</span></strong> <span>utilizados para controlar la respuesta inmunitaria del organismo tras un</span> <span>trasplante, que contengan ciclosporina</span></li><li><strong><span>medicamentos para la curaci&#243;n de &#250;lceras</span></strong> <span>que contengan sucralfato</span></li></ul><strong><span>Informe a su m&#233;dico si est&#225; tomando alguno de estos medicamentos.</span></strong> <span>No interrumpa su</span> <span>tratamiento sin consultar con su m&#233;dico.</span><p></p><p><strong><span>Consulte a su m&#233;dico o farmac&#233;utico si est&#225; tomando:</span></strong></p><ul><li><strong><span>anti&#225;cidos</span></strong> <span>para tratar &#250;lceras estomacales, acidez estomacal o reflujo &#225;cido, que contengan</span> <span>hidr&#243;xido de aluminio y/o de magnesio</span></li><li><strong><span>suplementos de minerales</span></strong> <span>o</span> <strong><span>de vitaminas,</span></strong> <span>que contengan magnesio o hierro</span></li></ul><strong><span>Consulte a su m&#233;dico o farmac&#233;utico antes de tomar Biktarvy</span></strong> <span>si est&#225; tomando alguno de estos</span> <span>medicamentos.</span><ol><li><p><strong><span>Anti&#225;cidos y suplementos de magnesio:</span></strong> <span>tendr&#225; que tomar Biktarvy al menos 2 horas</span> <strong><span>antes</span></strong> <span>de</span> <span>tomar los anti&#225;cidos o suplementos que contengan aluminio y/o magnesio. O puede tomar Biktarvy junto con alimentos al menos 2 horas</span> <strong><span>despu&#233;s</span></strong> <span>de la toma del anti&#225;cido o suplemento que contenga aluminio y/o magnesio.</span></p></li><li><p><strong><span>Suplementos de hierro:</span></strong> <span>tendr&#225; que tomar Biktarvy al menos 2 horas</span> <strong><span>antes</span></strong> <span>de tomar los</span> <span>suplementos de hierro o puede tomarlos todos juntos con alimentos.</span></p></li></ol><p><strong><span>Embarazo y lactancia</span></strong></p><ul><li><span>Si est&#225; embarazada o en periodo de lactancia, cree que podr&#237;a estar embarazada o tiene intenci&#243;n de quedarse embarazada, consulte a su m&#233;dico o farmac&#233;utico antes de utilizar este medicamento.</span></li><li><span>Informe a su m&#233;dico inmediatamente si se queda embarazada y pregunte sobre los posibles beneficios y riesgos de su tratamiento antirretroviral para usted y para su hijo.</span></li></ul><p><span>Si ha tomado Biktarvy durante su embarazo su m&#233;dico puede solicitar que se haga an&#225;lisis de sangre peri&#243;dicos y otras pruebas diagn&#243;sticas para controlar el desarrollo de su ni&#241;o. En ni&#241;os cuyas madres tomaron nucle&#243;sidos inhibidores de la transcriptasa inversa (ITIAN) durante el embarazo, el beneficio de la protecci&#243;n frente al VIH fue mayor que el riesgo de que se produjeran efectos adversos.</span></p><p><strong><span>No d&#233; el pecho a su hijo durante el tratamiento con Biktarvy.</span></strong> <span>Esto se debe a que algunos de los</span> <span>principios activos de este medicamento pasan a la leche materna. Se recomienda que no d&#233; el pecho para evitar que transmita el virus al ni&#241;o a trav&#233;s de la leche materna. Si realmente desea amamantar, hable primero con su m&#233;dico.</span></p><p><a name=\"page4\" id=\"page4\"></a><strong><span>Conducci&#243;n y uso de m&#225;quinas</span></strong></p><p><span>Biktarvy puede causar mareo. Si nota mareo durante el tratamiento con Biktarvy, no conduzca ni maneje herramientas o m&#225;quinas.</span></p><p><strong><span>Biktarvy contiene sodio</span></strong></p><p><span>Este medicamento contiene menos de 1 mmol de sodio (23 mg) por comprimido; esto es, esencialmente &#8220;exento de sodio&#8221;.</span></p></div>"
          }
        },
        {
          "title" : "3. Cómo tomar Biktarvy",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "3. Cómo tomar Biktarvy"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span>Siga exactamente las instrucciones de administraci&#243;n de este medicamento indicadas por su m&#233;dico.</span></p><p><span>En caso de duda, consulte de nuevo a su m&#233;dico o farmac&#233;utico.</span></p><p><strong><span>La dosis recomendada es:</span></strong></p><p><strong><span>Adultos:</span></strong> <span>un comprimido al d&#237;a, con o sin alimentos</span></p><p><span>No mastique, triture ni divida el comprimido.</span></p><strong><span>Consulte a su m&#233;dico o farmac&#233;utico si est&#225; tomando:</span></strong><ul><li><strong><span>anti&#225;cidos</span></strong> <span>para tratar &#250;lceras estomacales, acidez estomacal o reflujo &#225;cido, que contengan</span> <span>hidr&#243;xido de aluminio y/o de magnesio</span></li><li><strong><span>suplementos de minerales</span></strong> <span>o</span> <strong><span>vitaminas</span></strong> <span>que contengan magnesio o hierro</span></li></ul><strong><span>Vea la secci&#243;n 2 para m&#225;s informaci&#243;n</span></strong> <span>sobre c&#243;mo tomar estos medicamentos con Biktarvy.</span><p><strong><span>Si toma m&#225;s Biktarvy del que debe</span></strong></p><p><span>Si toma m&#225;s cantidad de la dosis recomendada de Biktarvy puede correr mayor riesgo de experimentar posibles efectos adversos con este medicamento (ver secci&#243;n 4,</span> <em><span>Posibles efectos adversos</span></em><span>).</span></p><p><span>Consulte inmediatamente a su m&#233;dico o acuda al servicio de urgencias m&#225;s cercano. Lleve consigo el frasco de comprimidos para que pueda describir f&#225;cilmente qu&#233; ha tomado.</span></p><p><strong><span>Si olvid&#243; tomar Biktarvy</span></strong></p><p><span>Es importante que no olvide una dosis de Biktarvy.</span></p><p><span>Si olvida una dosis:</span></p><ul><li><strong><span>Si se da cuenta en las 18 horas</span></strong> <span>posteriores a la hora a la que normalmente toma Biktarvy, debe</span> <span>tomar el comprimido tan pronto como sea posible. Luego tome la dosis siguiente de la forma habitual.</span></li><li><strong><span>Si se da cuenta despu&#233;s de 18 horas o m&#225;s</span></strong> <span>de la hora a la que normalmente toma Biktarvy, no</span> <span>tome la dosis olvidada. Espere y tome la siguiente dosis a la hora habitual.</span></li></ul><p><strong><span>Si vomita</span></strong> <span>antes de que transcurra 1 hora tras haber tomado Biktarvy, tome otro comprimido. Si</span> <span>vomita transcurrida 1 hora de haber tomado Biktarvy, no necesita tomar otro comprimido hasta el momento de la hora habitual.</span></p><p><strong><span>No interrumpa el tratamiento con Biktarvy</span></strong></p><p><strong><span>No interrumpa el tratamiento con Biktarvy sin hablar antes con su m&#233;dico.</span></strong> <span>Interrumpir Biktarvy</span> <span>puede afectar gravemente el funcionamiento de tratamientos futuros. Si se interrumpe Biktarvy por alg&#250;n motivo, consulte con su m&#233;dico antes de reiniciar la toma de comprimidos de Biktarvy.</span></p><p><a name=\"page5\" id=\"page5\"></a><strong><span>Cuando vea que le queda poca cantidad de Biktarvy,</span></strong> <span>acuda a su m&#233;dico o farmac&#233;utico para que le</span> <span>proporcione m&#225;s. Esto es muy importante, ya que la cantidad de virus puede empezar a aumentar si el medicamento se interrumpe incluso durante un corto periodo de tiempo. Es posible que entonces la enfermedad se vuelva m&#225;s dif&#237;cil de tratar.</span></p><p><strong><span>Si tiene infecci&#243;n por VIH y hepatitis B</span></strong> <span>es especialmente importante no suspender su tratamiento</span> <span>con Biktarvy sin antes hablar con su m&#233;dico. Puede necesitar hacerse an&#225;lisis de sangre durante varios meses tras suspender el tratamiento. En algunos pacientes con enfermedad hep&#225;tica avanzada o cirrosis no se recomienda suspender el tratamiento ya que esto puede producir un empeoramiento de su hepatitis, situaci&#243;n que puede ser potencialmente mortal.</span></p><strong><span>Hable con su m&#233;dico inmediatamente</span></strong> <span>acerca de s&#237;ntomas nuevos o inusuales tras suspender su</span> <span>tratamiento, particularmente s&#237;ntomas que asocie con la infecci&#243;n por el virus de la hepatitis B.</span><p><span>Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su m&#233;dico o farmac&#233;utico.</span></p></div>"
          }
        },
        {
          "title" : "4. Posibles efectos adversos",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "4. Posibles efectos adversos"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span>Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.</span></p><p><strong><span>Posibles efectos adversos: informe a un m&#233;dico inmediatamente</span></strong></p><ul><li><strong><span>Cualquier signo de inflamaci&#243;n o de infecci&#243;n.</span></strong> <span>En algunos pacientes con infecci&#243;n avanzada</span> <span>por el VIH (sida) y antecedentes de infecciones oportunistas (infecciones que ocurren en personas con un sistema inmunitario d&#233;bil), se pueden producir signos y s&#237;ntomas de inflamaci&#243;n por infecciones previas poco despu&#233;s de iniciar el tratamiento contra el VIH. Se cree que estos s&#237;ntomas se deben a una mejor&#237;a de la respuesta inmunitaria del organismo, que le permite combatir infecciones que podr&#237;an haber estado presentes sin s&#237;ntomas obvios.</span></li><li><span>Se pueden producir tambi&#233;n</span> <strong><span>trastornos autoinmunitarios,</span></strong> <span>en los que el sistema inmunitario ataca a los tejidos sanos del organismo, despu&#233;s de que empiece a tomar medicamentos para la infecci&#243;n por el VIH. Los trastornos autoinmunitarios se pueden producir muchos meses despu&#233;s del inicio del tratamiento. Est&#233; atento a cualquier s&#237;ntoma de infecci&#243;n u otros s&#237;ntomas, como:</span></li><li><span>debilidad muscular</span></li><li><span>debilidad que se inicia en las manos y los pies y se desplaza hacia el tronco</span></li><li><span>palpitaciones, temblor o hiperactividad</span></li></ul><strong><span>Si nota cualquiera de estos s&#237;ntomas o cualquier s&#237;ntoma de inflamaci&#243;n o infecci&#243;n, informe a su m&#233;dico inmediatamente.</span></strong><p><strong><span>Efectos adversos frecuentes</span></strong></p><p><em><span>(pueden afectar hasta 1 de cada 10 personas)</span></em></p><ul><li><span>depresi&#243;n</span></li><li><span>sue&#241;os anormales</span></li><li><span>dolor de cabeza</span></li><li><span>mareo</span></li><li><span>diarrea</span></li><li><span>ganas de vomitar (</span><em><span>n&#225;useas</span></em><span>)</span></li><li><span>cansancio (</span><em><span>fatiga</span></em><span>)</span></li></ul><p><strong><span>Efectos adversos poco frecuentes</span></strong></p><p><span>(</span><em><span>pueden afectar hasta 1 de cada 100 personas</span></em><span>)</span></p><ul><li><span>anemia</span></li><li><a name=\"page6\" id=\"page6\"></a><span>v&#243;mitos</span></li><li><span>dolor de est&#243;mago</span></li><li><span>problemas digestivos que generan molestias despu&#233;s de las comidas (</span><em><span>dispepsia</span></em><span>)</span></li><li><span>gases (</span><em><span>flatulencia</span></em><span>)</span></li><li><span>hinchaz&#243;n de la cara, labios, lengua o garganta (</span><em><span>angioedema</span></em><span>)</span></li><li><span>picaz&#243;n (</span><em><span>prurito</span></em><span>)</span></li><li><span>erupci&#243;n</span></li><li><span>habones (</span><em><span>urticaria</span></em><span>)</span></li><li><span>dolor en las articulaciones (</span><em><span>artralgia</span></em><span>)</span></li><li><span>comportamiento suicida</span></li><li><span>ansiedad</span></li><li><span>trastornos del sue&#241;o</span></li></ul><p><em><span>Los an&#225;lisis de sangre tambi&#233;n pueden mostrar:</span></em></p><ul><li><span>Concentraciones m&#225;s altas de sustancias llamadas bilirrubina y/o creatinina s&#233;rica en la sangre</span></li><li><strong><span>Si considera que alguno de los efectos adversos que sufre es grave, informe a su m&#233;dico.</span></strong></li></ul><p><strong><span>Otros efectos que se pueden observar durante el tratamiento contra el VIH</span></strong></p><p><span>La frecuencia de los siguientes efectos adversos se considera no conocida (la frecuencia no se puede estimar a partir de los datos disponibles).</span></p><ul><li><strong><span>Problemas &#243;seos.</span></strong> <span>Algunos pacientes tratados con medicamentos antirretrovirales combinados</span> <span>como Biktarvy pueden desarrollar una enfermedad de los huesos llamada</span> <em><span>osteonecrosis</span></em> <span>(muerte del tejido &#243;seo debida a una p&#233;rdida del suministro de sangre al hueso). Tomar este tipo de medicamentos durante un tiempo prolongado, tomar corticosteroides, beber alcohol, tener un sistema inmunitario muy d&#233;bil y tener sobrepeso, pueden ser algunos de los muchos factores de riesgo para desarrollar esta enfermedad. Los signos de osteonecrosis son:</span></li><ul><li><span>rigidez articular</span></li><li><span>molestias y dolores articulares (especialmente de la cadera, la rodilla y el hombro)</span></li><li><span>dificultad para moverse</span></li></ul></ul><strong><span>Si nota cualquiera de estos s&#237;ntomas, informe a su m&#233;dico.</span></strong><p><span>Durante el tratamiento del VIH puede haber un aumento en el peso y en los niveles de glucosa y l&#237;pidos en la sangre. Esto puede estar en parte relacionado con la recuperaci&#243;n de la salud y con el estilo de vida y, en el caso de los l&#237;pidos en la sangre, algunas veces con los medicamentos contra el VIH por s&#237; mismos. Su m&#233;dico le controlar&#225; estos cambios.</span></p><p><strong><span>Comunicaci&#243;n de efectos adversos</span></strong></p><p><span>Si experimenta cualquier tipo de efecto adverso, consulte a su m&#233;dico o farmac&#233;utico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. Tambi&#233;n puede comunicarlos directamente</span> <span>a trav&#233;s del sistema nacional de notificaci&#243;n incluido en el</span> <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span>Ap&#233;ndice V.</span></a> <span>Mediante la comunicaci&#243;n de efectos adversos usted puede contribuir a proporcionar m&#225;s informaci&#243;n sobre la seguridad de este medicamento.</span></p></div>"
          }
        },
        {
          "title" : "5. CONSERVACIÓN DE Biktarvy",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "5. CONSERVACIÓN DE Biktarvy"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span>Mantener este medicamento fuera de la vista y del alcance de los ni&#241;os.</span></p><p><span>No utilice este medicamento despu&#233;s de la fecha de caducidad que aparece en la caja y en el frasco despu&#233;s de {CAD}. La fecha de caducidad es el &#250;ltimo d&#237;a del mes que se indica.</span></p><p><span>Conservar en el embalaje original para protegerlo de la humedad. Mantener el frasco perfectamente cerrado. No utilizar si falta el sello del frasco o est&#225; roto.</span></p><p><a name=\"page7\" id=\"page7\"></a><span>Los medicamentos no se deben tirar por los desag&#252;es ni a la basura. Pregunte a su farmac&#233;utico c&#243;mo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudar&#225; a proteger el medio ambiente.</span></p><p><span>&#xa0;</span></p></div>"
          }
        },
        {
          "title" : "6. Contenido del envase e información adicional",
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi/",
              "code" : "100000155538"
            }],
            "text" : "6. Contenido del envase e información adicional"
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong><span>Composici&#243;n de Biktarvy</span></strong></p><p><strong><span>Los principios activos son</span></strong> <span>bictegravir, emtricitabina y tenofovir alafenamida. Cada comprimido de</span> <span>Biktarvy contiene bictegravir s&#243;dico equivalente a 50 mg de bictegravir, 200 mg de emtricitabina y tenofovir alafenamida fumarato equivalente a 25 mg de tenofovir alafenamida.</span></p><p><strong><span>Los dem&#225;s componentes son</span></strong></p><p><em><span>N&#250;cleo del comprimido</span></em></p><p><span>Celulosa microcristalina, croscarmelosa s&#243;dica, estearato de magnesio.</span></p><p><em><span>Recubrimiento con pel&#237;cula</span></em></p><p><span>Alcohol polivin&#237;lico, di&#243;xido de titanio (E171), macrogol, talco, &#243;xido de hierro rojo (E172), &#243;xido de hierro negro (E172).</span></p><p><strong><span>Aspecto del producto y contenido del envase</span></strong></p><p><span>Los comprimidos recubiertos con pel&#237;cula de Biktarvy son comprimidos recubiertos con pel&#237;cula de color marr&#243;n purp&#250;reo, con forma de c&#225;psula, marcados en una de las caras del comprimido con &#171;GSI&#187; y en la otra cara del comprimido con &#171;9883&#187;. Biktarvy se presenta en frascos de 30 comprimidos y en envases de 3 frascos, conteniendo cada uno de ellos 30 comprimidos. Cada frasco contiene un desecante de gel de s&#237;lice que debe conservarse en el frasco para ayudar a proteger los comprimidos. El desecante de gel de s&#237;lice est&#225; contenido en un sobre o recipiente separado, y no se debe tragar.</span></p><p><span>Puede que solamente est&#233;n comercializados algunos tama&#241;os de envases.</span></p><p><strong><span>Titular de la autorizaci&#243;n de comercializaci&#243;n</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Carrigtohill</span></p><p><span>County Cork, T45 DP77</span></p><p><span>Irlanda</span></p><p><strong><span>Responsable de la fabricaci&#243;n</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>IDA Business &#38; Technology Park</span></p><p><span>Carrigtohill</span></p><p><span>County Cork</span></p><p><span>Irlanda</span></p><p><span>Pueden solicitar m&#225;s informaci&#243;n respecto a este medicamento dirigi&#233;ndose al representante local del titular de la autorizaci&#243;n de comercializaci&#243;n:</span></p><table cellspacing=\"0\" cellpadding=\"0\"><tr><td><p><strong><span>Belgi&#235;/Belgique/Belgien</span></strong></p><p><span>Gilead Sciences Belgium SPRL-BVBA</span></p><p><span>T&#233;l/Tel: + 32 (0) 24 01 35 50</span></p></td><td><p><strong><span>Lietuva</span></strong></p><p><span>Gilead Sciences Poland Sp. z o.o.</span></p><p><span>Tel.: + 48 (0) 22 262 8702</span></p></td></tr><tr><td><p><strong><span>????????</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>???.: + 353 (0) 1 686 1888</span></p></td><td><p><strong><span>Luxembourg/Luxemburg</span></strong></p><p><span>Gilead Sciences Belgium SPRL-BVBA</span></p><p><span>T&#233;l/Tel: + 32 (0) 24 01 35 50</span></p></td></tr><tr><td><p><strong><span>Cesk&#225; republika</span></strong></p><p><span>Gilead Sciences s.r.o.</span></p><p><span>Tel: + 420 (0) 910 871 986</span></p></td><td><p><strong><span>Magyarorsz&#225;g</span></strong></p><p><span>Gilead Sciences</span> <span>Ireland UC</span></p><p><span>Tel.: + 353 (0) 1 686 1888</span></p></td></tr><tr><td><p><strong><span>Danmark</span></strong></p><p><span>Gilead Sciences Sweden AB</span></p><p><span>Tlf: + 46 (0) 8 5057 1849</span></p></td><td><p><strong><span>Malta</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td><p><strong><span>Deutschland</span></strong></p><p><span>Gilead Sciences GmbH</span></p><p><span>Tel: + 49 (0) 89 899890-0</span></p></td><td><p><strong><span>Nederland</span></strong></p><p><span>Gilead Sciences Netherlands B.V.</span></p><p><span>Tel: + 31 (0) 20 718 36 98</span></p></td></tr><tr><td><p><strong><span>Eesti</span></strong></p><p><span>Gilead Sciences Poland Sp. z o.o.</span></p><p><span>Tel.: +48 (0) 22 262 8702</span></p></td><td><p><strong><span>Norge</span></strong></p><p><span>Gilead Sciences Sweden AB</span></p><p><span>Tlf: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td><p><strong><span>&#917;&#955;&#955;?&#948;&#945;</span></strong></p><p><span>Gilead Sciences &#917;&#955;&#955;?&#962; &#924;.&#917;&#928;&#917;.</span></p><p><span>&#932;&#951;&#955;: + 30 (0) 210 8930 100</span></p></td><td><p><strong><span>&#214;sterreich</span></strong></p><p><span>Gilead Sciences GesmbH</span></p><p><span>Tel: + 43 (0) 1 260 830</span></p></td></tr><tr><td><p><strong><span>Espa&#241;a</span></strong></p><p><span>Gilead Sciences, S.L.</span></p><p><span>Tel: + 34 (0) 91 378 98 30</span></p></td><td><p><strong><span>Polska</span></strong></p><p><span>Gilead Sciences Poland Sp. z o.o.</span></p><p><span>Tel.: + 48 (0) 22 262 870</span><span>2</span></p></td></tr><tr><td><p><strong><span>France</span></strong></p><p><span>Gilead Sciences</span></p><p><span>T&#233;l: + 33 (0) 1 46 09 41 00</span></p></td><td><p><strong><span>Portugal</span></strong></p><p><span>Gilead Sciences, Lda.</span></p><p><span>Tel: + 351 (0) 21 7928790</span></p></td></tr><tr><td><p><strong><span>Hrvatska</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Tel: + 353 (0) 1 686 1888</span></p></td><td><p><strong><span>Rom&#226;nia</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td><p><strong><span>Irlanda</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Tel: + 353 (0) 214 825 999</span></p></td><td><p><strong><span>Slovenija</span></strong></p><p><span>Gilead Sciences Ireland UC</span></p><p><span>Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td><p><strong><span>&#205;sland</span></strong></p><p><span>Gilead Sciences Sweden AB</span></p><p><span>S&#237;mi: + 46 (0) 8 5057 1849</span></p></td><td><p><strong><span>Slovensk&#225; republika</span></strong></p><p><span>Gilead Sciences Slovakia s.r.o.</span></p><p><span>Tel: + 421 (0) 232 121 210</span></p></td></tr><tr><td><p><strong><span>Italia</span></strong></p><p><span>Gilead Sciences S.r.l.</span></p><p><span>Tel: + 39 02 439201</span></p></td><td><p><strong><span>Suomi/Finland</span></strong></p><p><span>Gilead Sciences Sweden AB</span></p><p><span>Puh/Tel: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td><p><strong><span>&#922;?&#960;&#961;&#959;&#962;</span></strong></p><p><span>Gilead Sciences &#917;&#955;&#955;?&#962; &#924;.&#917;&#928;&#917;.</span></p><p><span>&#932;&#951;&#955;: + 30 (0) 210 8930 100</span></p></td><td><p><strong><span>Sverige</span></strong></p><p><span>Gilead Sciences Sweden A</span><span>B</span></p><p><span>Tel: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td><p><strong><span>Latvija</span></strong></p><p><span>Gilead Sciences Poland Sp. z o.o.</span></p><p><span>Tel.: + 48 (0) 22 262 8702</span></p></td><td><p><strong><span>Reino Unido</span></strong></p><p><span>Gilead Sciences Ltd.</span></p><p><span>Tel: + 44 (0) 8000 113 700</span></p></td></tr></table><p><a name=\"page9\" id=\"page9\"></a><strong><span>Fecha de la &#250;ltima revisi&#243;n de este prospecto:</span></strong></p><p><span>La informaci&#243;n detallada de este medicamento est&#225; disponible en la p&#225;gina web de la Agencia Europea de Medicamentos:</span> <a href=\"http://www.ema.europa.eu/\"><span>http://www.ema.europa.eu.</span></a></p><p><span>&#xa0;</span></p></div>"
          }
        }]
      }]
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/ClinicalUseDefinition/cud-d79af6e660f456c6c7091803d6bd1a92",
    "resource" : {
      "resourceType" : "ClinicalUseDefinition",
      "id" : "cud-d79af6e660f456c6c7091803d6bd1a92",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-contraindication-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"ClinicalUseDefinition_cud-d79af6e660f456c6c7091803d6bd1a92\"> </a><p><b>Generated Narrative: ClinicalUseDefinition</b><a name=\"cud-d79af6e660f456c6c7091803d6bd1a92\"> </a><a name=\"hccud-d79af6e660f456c6c7091803d6bd1a92\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ClinicalUseDefinition &quot;cud-d79af6e660f456c6c7091803d6bd1a92&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-ClinicalUseDefinition-contraindication-uv-epi.html\">ClinicalUseDefinition Contraindication (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/rmswi/#/</code>/pregnancy\u00a0(use:\u00a0OFFICIAL)</p><p><b>type</b>: contraindication</p><p><b>subject</b>: <a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><blockquote><p><b>contraindication</b></p><h3>DiseaseSymptomProcedures</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>nan <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (mdr#nan)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/rmswi/#/",
        "value" : "pregnancy"
      }],
      "type" : "contraindication",
      "subject" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "contraindication" : {
        "diseaseSymptomProcedure" : {
          "concept" : {
            "coding" : [{
              "system" : "http://terminology.hl7.org/CodeSystem/mdr",
              "code" : "nan",
              "display" : "nan"
            }]
          }
        }
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-bictegravirsodium",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-bictegravirsodium",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-bictegravirsodium\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-bictegravirsodium\"> </a><a name=\"hcingredient-for-biktarvy-bictegravirsodium\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-bictegravirsodium&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/4L5MP1Y7W7\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>BICTEGRAVIR SODIUM <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#4L5MP1Y7W7)</span></td></tr></table><h3>Strengths</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style=\"display: none\">*</td><td>50 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html\">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "4L5MP1Y7W7"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072072",
          "display" : "Active"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "4L5MP1Y7W7",
              "display" : "BICTEGRAVIR SODIUM"
            }]
          }
        },
        "strength" : [{
          "presentationQuantity" : {
            "value" : 50,
            "system" : "http://unitsofmeasure.org",
            "code" : "mg"
          },
          "basis" : {
            "coding" : [{
              "system" : "http://terminology.hl7.org/CodeSystem/v3-RoleClass",
              "code" : "ACTIB",
              "display" : "active ingredient - basis of strength"
            }]
          }
        }]
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-emtricitabine",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-emtricitabine",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-emtricitabine\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-emtricitabine\"> </a><a name=\"hcingredient-for-biktarvy-emtricitabine\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-emtricitabine&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/G70B4ETF4S\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Emtricitabine <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#G70B4ETF4S)</span></td></tr></table><h3>Strengths</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style=\"display: none\">*</td><td>200 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html\">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "G70B4ETF4S"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072072",
          "display" : "Active"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "G70B4ETF4S",
              "display" : "Emtricitabine"
            }]
          }
        },
        "strength" : [{
          "presentationQuantity" : {
            "value" : 200,
            "system" : "http://unitsofmeasure.org",
            "code" : "mg"
          },
          "basis" : {
            "coding" : [{
              "system" : "http://terminology.hl7.org/CodeSystem/v3-RoleClass",
              "code" : "ACTIB",
              "display" : "active ingredient - basis of strength"
            }]
          }
        }]
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-tenofoviralafenamide",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-tenofoviralafenamide",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-tenofoviralafenamide\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-tenofoviralafenamide\"> </a><a name=\"hcingredient-for-biktarvy-tenofoviralafenamide\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-tenofoviralafenamide&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/EL9943AG5J\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>tenofovir alafenamide <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#EL9943AG5J)</span></td></tr></table><h3>Strengths</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style=\"display: none\">*</td><td>25 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html\">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "EL9943AG5J"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072072",
          "display" : "Active"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "EL9943AG5J",
              "display" : "tenofovir alafenamide"
            }]
          }
        },
        "strength" : [{
          "presentationQuantity" : {
            "value" : 25,
            "system" : "http://unitsofmeasure.org",
            "code" : "mg"
          },
          "basis" : {
            "coding" : [{
              "system" : "http://terminology.hl7.org/CodeSystem/v3-RoleClass",
              "code" : "ACTIB",
              "display" : "active ingredient - basis of strength"
            }]
          }
        }]
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-microcrystallinecellulose",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-microcrystallinecellulose",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-microcrystallinecellulose\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-microcrystallinecellulose\"> </a><a name=\"hcingredient-for-biktarvy-microcrystallinecellulose\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-microcrystallinecellulose&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/OP1R32D61U\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Microcrystalline cellulose <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#OP1R32D61U)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "OP1R32D61U"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072082",
          "display" : "Excipient"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "OP1R32D61U",
              "display" : "Microcrystalline cellulose"
            }]
          }
        }
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-croscarmellosesodium",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-croscarmellosesodium",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-croscarmellosesodium\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-croscarmellosesodium\"> </a><a name=\"hcingredient-for-biktarvy-croscarmellosesodium\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-croscarmellosesodium&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/M28OL1HH48\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Croscarmellose sodium <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#M28OL1HH48)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "M28OL1HH48"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072082",
          "display" : "Excipient"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "M28OL1HH48",
              "display" : "Croscarmellose sodium"
            }]
          }
        }
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-magnesiumstearate",
    "resource" : {
      "resourceType" : "Ingredient",
      "id" : "ingredient-for-biktarvy-magnesiumstearate",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Ingredient_ingredient-for-biktarvy-magnesiumstearate\"> </a><p><b>Generated Narrative: Ingredient</b><a name=\"ingredient-for-biktarvy-magnesiumstearate\"> </a><a name=\"hcingredient-for-biktarvy-magnesiumstearate\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Ingredient &quot;ingredient-for-biktarvy-magnesiumstearate&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html\">Ingredient (ePI)</a></p></div><p><b>identifier</b>: <code>https://gsrs.ncats.nih.gov/ginas/app/beta</code>/70097M6I30\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href=\"#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Magnesium stearate <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (beta#70097M6I30)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : {
        "use" : "official",
        "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
        "value" : "70097M6I30"
      },
      "status" : "active",
      "for" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      },
      {
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      },
      {
        "reference" : "AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "role" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072082",
          "display" : "Excipient"
        }]
      },
      "substance" : {
        "code" : {
          "concept" : {
            "coding" : [{
              "system" : "https://gsrs.ncats.nih.gov/ginas/app/beta",
              "code" : "70097M6I30",
              "display" : "Magnesium stearate"
            }]
          }
        }
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9",
    "resource" : {
      "resourceType" : "AdministrableProductDefinition",
      "id" : "ap-94a96e39cfdcd8b378d12dd4063065f9",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9\"> </a><p><b>Generated Narrative: AdministrableProductDefinition</b><a name=\"ap-94a96e39cfdcd8b378d12dd4063065f9\"> </a><a name=\"hcap-94a96e39cfdcd8b378d12dd4063065f9\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource AdministrableProductDefinition &quot;ap-94a96e39cfdcd8b378d12dd4063065f9&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-AdministrableProductDefinition-uv-epi.html\">AdministrableProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001</p><p><b>status</b>: active</p><p><b>formOf</b>: <a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>administrableDoseForm</b>: Tablet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073664)</span></p><p><b>unitOfPresentation</b>: Tablet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000002152)</span></p><p><b>producedFrom</b>: <a href=\"#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></p><blockquote><p><b>routeOfAdministration</b></p><p><b>code</b>: Oral use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073619)</span></p><h3>TargetSpecies</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td></tr><tr><td style=\"display: none\">*</td><td>Human <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000109093)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : [{
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      }],
      "status" : "active",
      "formOf" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "administrableDoseForm" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000073664",
          "display" : "Tablet"
        }]
      },
      "unitOfPresentation" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "200000002152",
          "display" : "Tablet"
        }]
      },
      "producedFrom" : [{
        "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
      }],
      "routeOfAdministration" : [{
        "code" : {
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi",
            "code" : "100000073619",
            "display" : "Oral use"
          }]
        },
        "targetSpecies" : [{
          "code" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi",
              "code" : "100000109093",
              "display" : "Human"
            }]
          }
        }]
      }]
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorization94a96e39cfdcd8b378d12dd4063065f90",
    "resource" : {
      "resourceType" : "RegulatedAuthorization",
      "id" : "authorization94a96e39cfdcd8b378d12dd4063065f90",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"RegulatedAuthorization_authorization94a96e39cfdcd8b378d12dd4063065f90\"> </a><p><b>Generated Narrative: RegulatedAuthorization</b><a name=\"authorization94a96e39cfdcd8b378d12dd4063065f90\"> </a><a name=\"hcauthorization94a96e39cfdcd8b378d12dd4063065f90\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource RegulatedAuthorization &quot;authorization94a96e39cfdcd8b378d12dd4063065f90&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-RegulatedAuthorization-uv-epi.html\">RegulatedAuthorization (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001\u00a0(use:\u00a0OFFICIAL)</p><p><b>subject</b>: <a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>type</b>: Marketing Authorisation <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#220000000061)</span></p><p><b>status</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2018-06-21 13:28:17+0000</p><p><b>holder</b>: <a href=\"#Organization_mah-715f8a161ed438d0584510e5b4512caa\">See above (Organization/mah-715f8a161ed438d0584510e5b4512caa)</a></p><p><b>regulator</b>: <a href=\"#Organization_mra-1133a7374c78f1d40f41885344f06a5a\">See above (Organization/mra-1133a7374c78f1d40f41885344f06a5a)</a></p></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      }],
      "subject" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "220000000061",
          "display" : "Marketing Authorisation"
        }]
      },
      "status" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/publication-status",
          "code" : "active",
          "display" : "Active"
        }]
      },
      "statusDate" : "2018-06-21T13:28:17Z",
      "holder" : {
        "reference" : "Organization/mah-715f8a161ed438d0584510e5b4512caa"
      },
      "regulator" : {
        "reference" : "Organization/mra-1133a7374c78f1d40f41885344f06a5a"
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-715f8a161ed438d0584510e5b4512caa",
    "resource" : {
      "resourceType" : "Organization",
      "id" : "mah-715f8a161ed438d0584510e5b4512caa",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Organization_mah-715f8a161ed438d0584510e5b4512caa\"> </a><p><b>Generated Narrative: Organization</b><a name=\"mah-715f8a161ed438d0584510e5b4512caa\"> </a><a name=\"hcmah-715f8a161ed438d0584510e5b4512caa\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Organization &quot;mah-715f8a161ed438d0584510e5b4512caa&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Organization-uv-epi.html\">Organization (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/omswi</code>/ORG-100008368\u00a0(use:\u00a0OFFICIAL)</p><p><b>active</b>: true</p><p><b>type</b>: Marketing authorisation holder <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#220000000034)</span></p><p><b>name</b>: Gilead Sciences Ireland UC</p><h3>Contacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Address</b></td></tr><tr><td style=\"display: none\">*</td><td>Carrigtohill, County Cork, T45 County Cork IR(WORK)</td></tr></table></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/omswi",
        "value" : "ORG-100008368"
      }],
      "active" : true,
      "type" : [{
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "220000000034",
          "display" : "Marketing authorisation holder"
        }]
      }],
      "name" : "Gilead Sciences Ireland UC",
      "contact" : [{
        "address" : {
          "use" : "work",
          "type" : "physical",
          "text" : "Carrigtohill, County Cork, T45 County Cork IR",
          "line" : ["Carrigtohill, County Cork, T45"],
          "city" : "County Cork",
          "country" : "IR"
        }
      }]
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/Organization/mra-1133a7374c78f1d40f41885344f06a5a",
    "resource" : {
      "resourceType" : "Organization",
      "id" : "mra-1133a7374c78f1d40f41885344f06a5a",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Organization_mra-1133a7374c78f1d40f41885344f06a5a\"> </a><p><b>Generated Narrative: Organization</b><a name=\"mra-1133a7374c78f1d40f41885344f06a5a\"> </a><a name=\"hcmra-1133a7374c78f1d40f41885344f06a5a\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Organization &quot;mra-1133a7374c78f1d40f41885344f06a5a&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Organization-uv-epi.html\">Organization (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/omswi</code>/ORG-100013412\u00a0(use:\u00a0OFFICIAL)</p><p><b>active</b>: true</p><p><b>type</b>: Medicines Regulatory Authority <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#220000000032)</span></p><p><b>name</b>: European Medicines Agency</p><h3>Contacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Address</b></td></tr><tr><td style=\"display: none\">*</td><td>Carretera De Martorell 41 61, Poligono Industrial Nord-Est Amsterdam NL(WORK)</td></tr></table></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/omswi",
        "value" : "ORG-100013412"
      }],
      "active" : true,
      "type" : [{
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "220000000032",
          "display" : "Medicines Regulatory Authority"
        }]
      }],
      "name" : "European Medicines Agency",
      "contact" : [{
        "address" : {
          "use" : "work",
          "type" : "physical",
          "text" : "Carretera De Martorell 41 61, Poligono Industrial Nord-Est Amsterdam NL",
          "line" : ["Carretera De Martorell 41 61, Poligono Industrial Nord-Est"],
          "city" : "Amsterdam",
          "postalCode" : "1083 HS",
          "country" : "NL"
        }
      }]
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-e34e4b65abd3fd8e667db05606cc25a9",
    "resource" : {
      "resourceType" : "PackagedProductDefinition",
      "id" : "ppd-e34e4b65abd3fd8e667db05606cc25a9",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"PackagedProductDefinition_ppd-e34e4b65abd3fd8e667db05606cc25a9\"> </a><p><b>Generated Narrative: PackagedProductDefinition</b><a name=\"ppd-e34e4b65abd3fd8e667db05606cc25a9\"> </a><a name=\"hcppd-e34e4b65abd3fd8e667db05606cc25a9\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource PackagedProductDefinition &quot;ppd-e34e4b65abd3fd8e667db05606cc25a9&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-PackagedProductDefinition-uv-epi.html\">PackagedProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001\u00a0(use:\u00a0OFFICIAL)</p><p><b>name</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 90</p><p><b>type</b>: Chemical Medicinal Product <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000155527)</span></p><p><b>packageFor</b>: <a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>status</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2012-02-07 13:28:17+0000</p><blockquote><p><b>packaging</b></p><p><b>type</b>: Box <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073498)</span></p><p><b>quantity</b>: 1</p><p><b>material</b>: Cardboard <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000003529)</span></p><blockquote><p><b>packaging</b></p><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/654321</p><p><b>type</b>: Child-resistant closure <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073504)</span></p><p><b>quantity</b>: 90</p><p><b>material</b>: PolyVinyl Chloride <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000003222)</span></p><blockquote><p><b>containedItem</b></p></blockquote></blockquote></blockquote></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      }],
      "name" : "Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 90",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000155527",
          "display" : "Chemical Medicinal Product"
        }]
      },
      "packageFor" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "status" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/publication-status",
          "code" : "active",
          "display" : "Active"
        }]
      },
      "statusDate" : "2012-02-07T13:28:17Z",
      "packaging" : {
        "type" : {
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi",
            "code" : "100000073498",
            "display" : "Box"
          }]
        },
        "quantity" : 1,
        "material" : [{
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi",
            "code" : "200000003529",
            "display" : "Cardboard"
          }]
        }],
        "packaging" : [{
          "identifier" : [{
            "system" : "https://spor.ema.europa.eu/pmswi",
            "value" : "654321"
          }],
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi",
              "code" : "100000073504",
              "display" : "Child-resistant closure"
            }]
          },
          "quantity" : 90,
          "material" : [{
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi",
              "code" : "200000003222",
              "display" : "PolyVinyl Chloride"
            }]
          }],
          "containedItem" : [{
            "item" : {
              "reference" : {
                "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
              }
            }
          }]
        }]
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-6d93344139a7793e7b9bd0f5e32b6c91",
    "resource" : {
      "resourceType" : "PackagedProductDefinition",
      "id" : "ppd-6d93344139a7793e7b9bd0f5e32b6c91",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"PackagedProductDefinition_ppd-6d93344139a7793e7b9bd0f5e32b6c91\"> </a><p><b>Generated Narrative: PackagedProductDefinition</b><a name=\"ppd-6d93344139a7793e7b9bd0f5e32b6c91\"> </a><a name=\"hcppd-6d93344139a7793e7b9bd0f5e32b6c91\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource PackagedProductDefinition &quot;ppd-6d93344139a7793e7b9bd0f5e32b6c91&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-PackagedProductDefinition-uv-epi.html\">PackagedProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001\u00a0(use:\u00a0OFFICIAL)</p><p><b>name</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 30</p><p><b>type</b>: Chemical Medicinal Product <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000155527)</span></p><p><b>packageFor</b>: <a href=\"#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>status</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2012-02-07 13:28:17+0000</p><blockquote><p><b>packaging</b></p><p><b>type</b>: Box <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073498)</span></p><p><b>quantity</b>: 1</p><p><b>material</b>: Cardboard <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000003529)</span></p><blockquote><p><b>packaging</b></p><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/654321</p><p><b>type</b>: Child-resistant closure <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000073504)</span></p><p><b>quantity</b>: 30</p><p><b>material</b>: PolyVinyl Chloride <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000003222)</span></p><blockquote><p><b>containedItem</b></p></blockquote></blockquote></blockquote></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      }],
      "name" : "Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 30",
      "type" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000155527",
          "display" : "Chemical Medicinal Product"
        }]
      },
      "packageFor" : [{
        "reference" : "MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"
      }],
      "status" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/publication-status",
          "code" : "active",
          "display" : "Active"
        }]
      },
      "statusDate" : "2012-02-07T13:28:17Z",
      "packaging" : {
        "type" : {
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi",
            "code" : "100000073498",
            "display" : "Box"
          }]
        },
        "quantity" : 1,
        "material" : [{
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/rmswi",
            "code" : "200000003529",
            "display" : "Cardboard"
          }]
        }],
        "packaging" : [{
          "identifier" : [{
            "system" : "https://spor.ema.europa.eu/pmswi",
            "value" : "654321"
          }],
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi",
              "code" : "100000073504",
              "display" : "Child-resistant closure"
            }]
          },
          "quantity" : 30,
          "material" : [{
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/rmswi",
              "code" : "200000003222",
              "display" : "PolyVinyl Chloride"
            }]
          }],
          "containedItem" : [{
            "item" : {
              "reference" : {
                "reference" : "ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"
              }
            }
          }]
        }]
      }
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949",
    "resource" : {
      "resourceType" : "MedicinalProductDefinition",
      "id" : "mp2a9c4333cfd126f2e7b73ad3cafd6949",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949\"> </a><p><b>Generated Narrative: MedicinalProductDefinition</b><a name=\"mp2a9c4333cfd126f2e7b73ad3cafd6949\"> </a><a name=\"hcmp2a9c4333cfd126f2e7b73ad3cafd6949\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicinalProductDefinition &quot;mp2a9c4333cfd126f2e7b73ad3cafd6949&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-MedicinalProductDefinition-uv-epi.html\">MedicinalProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001, <code>https://www.who-umc.org/phpid</code>/0xF79CABF272B6A7EEF104DDDA44E827gy</p><p><b>type</b>: Medicinal Product <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-medicinal-product-type.html\">Medicinal Product Type</a>#MedicinalProduct)</span></p><p><b>domain</b>: Human use <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-medicinal-product-domain.html\">Medicinal Product Domain</a>#Human)</span></p><p><b>status</b>: active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#100000072084)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion</p><p><b>type</b>: Full name <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000001)</span></p><blockquote><p><b>part</b></p><p><b>part</b>: Biktarvy</p><p><b>type</b>: Invented name part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000002)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: bictegravir/emtricitabine/tenofovir alafenamide</p><p><b>type</b>: Scientific name part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000003)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: 50 mg/200 mg/25 mg</p><p><b>type</b>: Strength part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000004)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: film-coated tablets</p><p><b>type</b>: Pharmaceutical dose form part <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (220000000000#220000000005)</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td>United Kingdom <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#GBR)</span></td><td>United Kingdom <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#GBR)</span></td><td>English <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html\">Tags for the Identification of Languages</a>#en)</span></td></tr></table></blockquote></div>"
      },
      "identifier" : [{
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      },
      {
        "system" : "https://www.who-umc.org/phpid",
        "value" : "0xF79CABF272B6A7EEF104DDDA44E827gy"
      }],
      "type" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/medicinal-product-type",
          "code" : "MedicinalProduct",
          "display" : "Medicinal Product"
        }]
      },
      "domain" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/medicinal-product-domain",
          "code" : "Human",
          "display" : "Human use"
        }]
      },
      "status" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/publication-status",
          "code" : "active",
          "display" : "active"
        }]
      },
      "legalStatusOfSupply" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "100000072084",
          "display" : "Medicinal product subject to medical prescription"
        }]
      },
      "name" : [{
        "productName" : "Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion",
        "type" : {
          "coding" : [{
            "system" : "https://spor.ema.europa.eu/lists/220000000000",
            "code" : "220000000001",
            "display" : "Full name"
          }]
        },
        "part" : [{
          "part" : "Biktarvy",
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/lists/220000000000",
              "code" : "220000000002",
              "display" : "Invented name part"
            }]
          }
        },
        {
          "part" : "bictegravir/emtricitabine/tenofovir alafenamide",
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/lists/220000000000",
              "code" : "220000000003",
              "display" : "Scientific name part"
            }]
          }
        },
        {
          "part" : "50 mg/200 mg/25 mg",
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/lists/220000000000",
              "code" : "220000000004",
              "display" : "Strength part"
            }]
          }
        },
        {
          "part" : "film-coated tablets",
          "type" : {
            "coding" : [{
              "system" : "https://spor.ema.europa.eu/lists/220000000000",
              "code" : "220000000005",
              "display" : "Pharmaceutical dose form part"
            }]
          }
        }],
        "usage" : [{
          "country" : {
            "coding" : [{
              "system" : "urn:iso:std:iso:3166",
              "code" : "GBR",
              "display" : "United Kingdom"
            }]
          },
          "jurisdiction" : {
            "coding" : [{
              "system" : "urn:iso:std:iso:3166",
              "code" : "GBR",
              "display" : "United Kingdom"
            }]
          },
          "language" : {
            "coding" : [{
              "system" : "urn:ietf:bcp:47",
              "code" : "en",
              "display" : "English"
            }]
          }
        }]
      }]
    }
  },
  {
    "fullUrl" : "http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9",
    "resource" : {
      "resourceType" : "ManufacturedItemDefinition",
      "id" : "mid-94a96e39cfdcd8b378d12dd4063065f9",
      "meta" : {
        "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9\"> </a><p><b>Generated Narrative: ManufacturedItemDefinition</b><a name=\"mid-94a96e39cfdcd8b378d12dd4063065f9\"> </a><a name=\"hcmid-94a96e39cfdcd8b378d12dd4063065f9\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ManufacturedItemDefinition &quot;mid-94a96e39cfdcd8b378d12dd4063065f9&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-ManufacturedItemDefinition-uv-epi.html\">ManufacturedItemDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://spor.ema.europa.eu/pmswi</code>/EU/1/18/1289/001\u00a0(use:\u00a0OFFICIAL)</p><p><b>status</b>: active</p><p><b>manufacturedDoseForm</b>: Tablet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#100000073664)</span></p><p><b>unitOfPresentation</b>: Tablet <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (rmswi#200000002152)</span></p></div>"
      },
      "identifier" : [{
        "use" : "official",
        "system" : "https://spor.ema.europa.eu/pmswi",
        "value" : "EU/1/18/1289/001"
      }],
      "status" : "active",
      "manufacturedDoseForm" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi/",
          "code" : "100000073664",
          "display" : "Tablet"
        }]
      },
      "unitOfPresentation" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "200000002152",
          "display" : "Tablet"
        }]
      }
    }
  }]
}